Current Report Filing (8-k)
October 01 2021 - 6:03AM
Edgar (US Regulatory)
0001415684
false
0001415684
2021-09-23
2021-09-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
September
23, 2021
Date
of report (date of earliest event reported)
MusclePharm
Corporation
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53166
|
|
77-0664193
|
(State
or other jurisdictions of
incorporation
or organization)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
3753
Howard Hughes Parkway, Ste 200-849, Las Vegas, NV 89169
(Address
of principal executive offices) (Zip Code)
(800)
292-3909
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
N/A
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01
|
Entry
into a Material Definitive Agreement.
|
On
September 23, 2021, MusclePharm Corporation (the “Company”) and NBF Holdings Canada Inc. (“Nutrablend”)
entered into an Amendment to a Settlement Agreement (“Amended Agreement”) that was originally entered into
on September 25, 2020. Pursuant to the Amended Agreement, the Company is no longer obligated to issue Purchase Orders to Nutrablend
as stated in the Settlement Agreement, which, as stated in the Initial 8-K dated September 25, 2020, consisted of at least (i)
$1,500,000 from September 1, 2020 through November 30, 2020; (ii) $1,800,000 from December 1, 2020 through February 28, 2021; (iii) $2,100,000
from March 1, 2021 through May 31, 2021; (iv) $2,100,000 from June 1, 2021 through August 31, 2021; and (v) $1,400,000 from September
1, 2021 through October 30, 2021. The Monthly Payments provision of the Settlement Agreement remains unchanged.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MUSCLEPHARM
CORPORATION
|
|
|
|
By:
|
/s/
Ryan Drexler
|
|
Name:
|
Ryan
Drexler Title: Chief Executive Officer
|
Date:
September 30, 2021
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Sep 2023 to Sep 2024